Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

岁序更新，征程再启。在具身智能浪潮奔涌、机器人产业迈向全面升级的 2025 年，我们比任何时候都更需要 灯塔，更需要 领军力量 。 谁是穿越技术周期、引领产业方向的中流砥柱？谁在定义市场格局、开拓全球边疆的商业战场？谁，又能代表 " 中国智造 " 在机器人产业链领域的最强音？ 作为中国机器人领域一年一度的权威盘点与风向标， 2025 年第六届 LeadeRobot 中国机器人行业评选的帷 幕于11月15日正式拉开，奖项申报通道全面开启！寻找中国机器人产业的领军者！ ▍ 我们为何设计这些奖项？ 2025 年被视为人形机器人的量产元年， 行业正从技术演示迈向商业落地的临界点 ， 人形机器人与具身智能 行业正进入 1-N 的快速 发展阶段 ，全球超过一半的人形机器人与具身智能公司位于中国。 服务与特种机器人正以前所未有的深度和广度融入社会经济生活，本次奖项将发掘医疗机器人市场取得领先地 位 的企业，还希望发掘 成功开拓海外市场的商用机器人 头部 ，以及在复杂环境中大显身手的特种机器人。 如果说机器人整机是闪耀在舞台中央的明星，那么 核心零部件就是支撑其辉煌演出的基石与血脉。 机器人的 整体性能上限，取决于其最薄弱的 ...

2025 年，一场以"具身智能"为核心的全球竞赛，已经全面打响。从全球实验室竞相突破的通用机器人原型， 到各国产业政策密集落地的智能体战略；从跨国巨头重金布局的全栈技术生态，到初创新锐颠覆传统的场景创 新； 从硅谷的实验室到杭州的"六小龙"，在这场定义未来的全球竞赛中，领军企业与变革新星共同勾勒出产 业发展的双主线。 2025 年，中国"十四五"的收官之年，也是"十五五"的酝酿之年，市场呈现出"产融齐升、结构优化"的强劲增长 态势。我们看见，一批深耕多年的中国机器人领军企业，正以硬核的技术积淀与大规模市场场景适配能力，在 全球产业链中奠定"中国分量"；我们亦看见， 一群聚焦于 AI 与机器人融合赛道的创新者，正以颠覆性的构想 与闪电般的成长，在无人区点亮"中国火花"。 2025 年，机器人与 具身智能 不再是业界陌生的 新概念，它正以前所未有的速度从实验室走向产业界 ， 其 也已经不再局限于业内的狂欢，更是全人类关注的共同话题。 如果说过去十年 ， 是人工智能在 " 云端 " 狂 飙突进的十年，那么下一个十年， 更多人开始相信， 将是智能体 " 落地生根 " 的十年。 这个 " 根 " ，便是 各类 机器人的 ...

Core Viewpoint - The company will hold an investor briefing on November 19, 2025, to discuss its Q3 2025 performance and financial results, allowing for interactive communication with investors [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for November 19, 2025, from 15:00 to 16:00 [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible online [4]. - The format of the meeting will be an online text interaction, enabling real-time communication with investors [3][5]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date [5]. - A pre-question submission period is available from November 12 to November 18, 2025, allowing investors to submit questions via the website or email [5]. - The company will address commonly asked questions during the briefing [3][5]. Group 3: Contact Information - The contact for inquiries is the Securities Investment Department, reachable at 010-82156660-8009 or via email at tinavi@tinavi.com [6]. Group 4: Additional Information - After the briefing, investors can view the meeting's details and main content on the Shanghai Stock Exchange Roadshow Center [7].

● 会议召开时间：2025年11月19日15:00-16:00 ● 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/）（以下简称"上 证路演中心"） ● 会议召开方式：上证路演中心网络文字互动 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688277 证券简称：天智航 公告编号：2025-044 北京天智航医疗科技股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 四、投资者参加方式 （一）投资者可在2025年11月19日15:00-16:00，通过互联网登录上证路演中心 （https://roadshow.sseinfo.com/），在线参与本次业绩说明会，公司将及时回答投资者的提问。 （二）投资者可于2025年11月12日至11月18日16:00前登录上证路演中心网站首页，点击"提问预征 集"栏目（https://roadshow.sseinfo.com/preCallQa）， ...

证券代码：688277 证券简称：天智航 公告编号：2025-044 北京天智航医疗科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 12 日至 11 月 18 日 16:00 前登录上证路演中心 网站首页点击"提问预征集"栏目或通过公司邮箱 tinavi@tinavi.com 进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京天智航医疗科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 19 日 15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第三季度 的经营成果及财务指标的具体情况与投资者进行互动交 ...

Key Points - The stock price of HeFu China has seen a significant short-term increase, indicating potential market sentiment overheating and irrational speculation risks [1] - Hongxing Development plans to invest 149 million yuan to establish a new high-purity thiourea project with an annual capacity of 20,000 tons [1] - Tongda Co., Ltd. is expected to win a bid for a 133 million yuan project with the State Grid [1] - Qiangrui Technology intends to acquire a 35% stake in Alubao Technology [1] - KJ Intelligent has repurchased a total of 6.6628% of its shares [1] - Hanma Technology reported cumulative vehicle sales of 10,797 units in the first ten months, representing a year-on-year increase of 45.63% [1] - Boying Special Welding plans to reduce its holdings by no more than 3% [1] - Ruijian Technology is collaborating with Tailan New Energy in the field of solid-state batteries and key materials [1] - The board member and deputy general manager of Siwei Liekong has been detained and is under investigation [1]

Summary of Key Points Core Viewpoint - Several shareholders from various companies are planning to reduce their stakes, indicating potential shifts in ownership and market sentiment. Additionally, some companies are facing significant regulatory actions, including delisting risks and investigations. Group 1: Shareholder Reductions - Montai High-tech's shareholders Guo Xianrui and Guo Lishuang plan to reduce their holdings by no more than 3% [1] - Boying Special Welding's shareholders Qianhai Equity Fund and Zhongyuan Qianhai Fund intend to reduce their stakes by no more than 3% [1] - Aerospace Intelligence's shareholder China Lucky plans to reduce its holdings by no more than 2.5% [1] - Ruifeng New Materials' shareholder Sinopec Capital aims to reduce its stake by no more than 1% [1] - Tianzhihang's shareholders Advanced Manufacturing Fund and Beijing-Tianjin-Hebei Fund plan to collectively reduce their holdings by no more than 3% [1] - Bull Group's actual controller Ruan Xueping has conducted a block trade to reduce 1.21% of the company's shares [1] - Other companies with notable reductions include Jiaoda Sino (up to 500,000 shares), Fangzhi Technology (up to 3%), and Shengyi Technology (up to 1%) [1] Group 2: Regulatory Actions and Investigations - ST Zhangjiajie will have its stock trading subject to additional delisting risk warnings and will be suspended [1] - Anpelong plans to terminate its 2025 restricted stock incentive plan [1] - Siwei Control's director and deputy general manager Zhao Jianzhou has been detained and is under investigation [1] - *ST Gaohong has been informed by the Shenzhen Stock Exchange that its stock will be delisted [1]

智通财经APP讯，天智航(688277.SH)发布公告，公司于近日收到先进制造基金及其一致行动人京津冀 基金出具的《关于北京天智航医疗科技股份有限公司的股份减持计划告知函》，先进制造基金拟在本次 减持计划公告之日起15个交易日后的三个月内，以集中竞价方式择机减持其所持公司股份合计不超过 228万股，即不超过公司总股本的0.50%，以大宗交易方式择机减持其所持公司股份合计不超过455.99万 股，即不超过公司总股本的1%;京津冀基金拟在本次减持计划公告之日起15个交易日后的三个月内，以 集中竞价方式择机减持其所持公司股份合计不超过228万股，即不超过公司总股本的0.50%，以大宗交 易方式择机减持其所持公司股份合计不超过455.99万股，即不超过公司总股本的1%。 ...

证券代码：688277 证券简称：天智航 公告编号：2025-043 减持计划的主要内容 公司于近日收到先进制造基金及其一致行动人京津冀基金出具的《关于北 京天智航医疗科技股份有限公司的股份减持计划告知函》，先进制造基金拟在本 次减持计划公告之日起 15 个交易日后的三个月内，以集中竞价方式择机减持其 所持公司股份合计不超过 2,279,960 股，即不超过公司总股本的 0.50%，以大宗 交易方式择机减持其所持公司股份合计不超过 4,559,920 股，即不超过公司总股 本的 1.00%；京津冀基金拟在本次减持计划公告之日起 15 个交易日后的三个月 内，以集中竞价方式择机减持其所持公司股份合计不超过 2,279,960 股，即不超 过公司总股本的 0.50%，以大宗交易方式择机减持其所持公司股份合计不超过 4,559,920 股，即不超过公司总股本的 1.00%。先进制造基金及其一致行动人京津 冀基金在任意连续 90 日内通过集中竞价方式减持公司股份的总数合计不超过公 司股份总数的 1%，在任意连续 90 日内通过大宗交易方式减持公司股份的总数合 计不超过公司股份总数的 2%。若减持计划期间公司有送股、资 ...